NEW YORK (GenomeWeb News) – Interleukin Genetics today said that the corporate compliance staff of the New York Stock Exchange Amex has granted the firm an extension to meet the exchange's continued listing standards.
The Waltham, Mass.-based genetic test maker will remain listed on the NYSE Amex up to June 23, subject to periodic review by the exchange staff of the firm's progress toward regaining compliance.
Interleukin had received a letter of non-compliance from the New York Stock Exchange Alternext, which now includes listings on Amex following the NYSE's acquisition, in December 2008 saying that the firm was not in compliance with the exchange's regulations. Its stockholders' equity was less than $6 million and it had reported losses from continuing operations and net losses in its five most recent fiscal years leading up to the letter.
Two months ago, Interleukin filed a shelf registration with the US Securities and Exchange Commission seeking to sell up to $75 million worth of stock or debt instruments.
The firm is scheduled to release its fourth-quarter and fiscal-year 2009 results later this week.